Adc Therapeutics Sa Revenue Growth Rates (ADCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adc Therapeutics Sa  (NYSE: ADCT)
 

ADCT's Revenue Growth by Quarter and Year

Adc Therapeutics Sa's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 19.25
1st Quarter March 20.85
FY 40.10

ADCTs Annual Revenue
Adc Therapeutics Sa's Revenue in the fiscal year 2025 $ 81.36 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2024 $ 70.84 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2023 $ 69.56 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2022 $ 209.91 millions
Adc Therapeutics Sa's Revenue in the fiscal year 2021 $ 33.92 millions




ADCT Revenue second quarter 2026 Y/Y Growth Comment
Adc Therapeutics Sa reported Revenue growth of 2.17% year on year in the second quarter 2026, to $ 19.25 millions, this is lower than Adc Therapeutics Sa's recent average Revenue improvement of 37.81%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 112 other companies have achieved higher Revenue growth. While Adc Therapeutics Sa' s Revenue increase of 2.17% ranks overall at the positon no. 2390 in the second quarter 2026.


ADCT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 36.37 % 0.71 % -92 %
3rd Quarter September - -11 % 27.4 % -81.01 %
2nd Quarter June 2.17 % 8.21 % -9.7 % 11.51 %
1st Quarter March -9.47 % 27.59 % -4.95 % -59.16 %
FY   - 14.87 % 1.84 % -

Financial Statements
Adc Therapeutics Sa's second quarter 2026 Revenue $ 19.25 millions ADCT's Income Statement
Adc Therapeutics Sa's second quarter 2025 Revenue $ 18.84 millions Quarterly ADCT's Income Statement


ADCT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 40.35 % -8.4 % 15.87 %
3rd Quarter September - -12.79 % 6.03 % -24.84 %
2nd Quarter June -7.68 % -18.19 % -3.55 % 1.53 %
1st Quarter March -9.58 % 36.19 % 7.5 % -90.95 %
FY (Year on Year)   - 14.87 % 1.84 % -


Back to ADCT Growth rate Comparisons >> Back to ADCT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #113
Healthcare Sector #348
Overall #2390

Revenue Y/Y Growth Statistics
High Average Low
931.98 % 37.81 % -80.13 %
(Dec 31 2022)   (Dec 31 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #113
Healthcare Sector #348
Overall #2390
Revenue Y/Y Growth Statistics
High Average Low
931.98 % 37.81 % -80.13 %
(Dec 31 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Adc Therapeutics Sa's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
341.39 % 19.9 % -90.95 %
0  


ADCT's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Adc Therapeutics Sa disclosed drop in Revenue from the first quarter by -7.68% to $ 19.25 millions, from $ 20.85 millions achived in the previous reporting period.

But that's not important problem, as Adc Therapeutics Sa's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Revenue quarter on quarter growth. While Adc Therapeutics Sa's Revenue growth quarter on quarter, overall rank is 2665.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #332
Overall #2665
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #332
Overall #2665
Revenue Q/Q Growth Statistics
High Average Low
341.39 % 19.9 % -90.95 %
0  


ADCT's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Adc Therapeutics Sa disclosed drop in Revenue from the first quarter by -7.68% to $ 19.25 millions, from $ 20.85 millions achived in the previous reporting period.

But that's not important problem, as Adc Therapeutics Sa's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Revenue quarter on quarter growth. While Adc Therapeutics Sa's Revenue growth quarter on quarter, overall rank is 2665.


Adc Therapeutics Sa's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 79.58 $ 79.18 $ 81.36 $ 75.21 $ 77.25
Y / Y Revenue Growth (TTM) 3.03 % 4.43 % 14.85 % 6.35 % 15.73 %
Year on Year Revenue Growth Overall Ranking # 1052 # 2934 # 2586 # 3073 # 2914
Seqeuential Revenue Change (TTM) 0.52 % -2.68 % 8.17 % -2.64 % 1.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 2390 # 1448 # 2547 # 3290 # 3197


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adc Therapeutics Sa's cumulative twelve months Revenue were $ 80 millions, company would post below average annual Revenue growth of 1.88% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adc Therapeutics Sa's Revenue growth from the 20.85% growth in Mar 31 2026.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1052, from total ranking in previous quarter at 2934.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 203
Overall # 1052

Revenue TTM Y/Y Growth Statistics
High Average Low
931.98 %
 37.81 %
-80.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 348
S&P 500 # 2390
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adc Therapeutics Sa's cumulative twelve months Revenue were $ 80 millions, company would post below average annual Revenue growth of -80.13% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adc Therapeutics Sa's Revenue growth from the 20.85% growth in Mar 31 2026.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1052, from total ranking in previous quarter at 2934.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 113
Healthcare Sector # 203
Overall # 1052

Revenue TTM Y/Y Growth Statistics
High Average Low
931.98 %
37.81 %
-80.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 113
Sector # 348
S&P 500 # 2390




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADCT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bioventus Inc 3.76%$ 3.757 millions
Heron Therapeutics Inc 3.64%$ 3.640 millions
Prime Medicine Inc 3.50%$ 3.498 millions
Inogen Inc 3.04%$ 3.042 millions
Pacific Health Care Organization Inc2.79%$ 2.786 millions
Quidelortho Corp2.77%$ 2.769 millions
C4 Therapeutics Inc 2.75%$ 2.754 millions
Surgery Partners Inc 2.75%$ 2.748 millions
Lantheus Holdings Inc 2.69%$ 2.690 millions
Healthcare Services Group Inc 2.69%$ 2.686 millions
Adma Biologics Inc 2.61%$ 2.613 millions
Pfizer Inc2.60%$ 2.600 millions
Infusystem Holdings Inc2.59%$ 2.586 millions
Outset Medical Inc 2.49%$ 2.488 millions
3m Company2.46%$ 2.459 millions
Strata Critical Medical Inc 2.41%$ 2.408 millions
Nature s Sunshine Products inc 2.35%$ 2.350 millions
Solventum Corporation2.22%$ 2.221 millions
Adc Therapeutics Sa2.17%$ 2.171 millions
Moderna Inc 2.11%$ 2.113 millions
Co diagnostics Inc 1.98%$ 1.977 millions
Rxsight Inc 1.66%$ 1.660 millions
Bioage Labs Inc 1.62%$ 1.617 millions
Icon Plc1.20%$ 1.197 millions


About Adc Therapeutics Sa Revenue Growth Rates (ADCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Adc Therapeutics Sa (CIK 1771910).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-056711
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Adc Therapeutics Sa’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.